lobbying_activities: 2634854

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2634854	6e91c212-04f3-4999-a98a-3b55bf3d7fe7	Q2	BUCHANAN INGERSOLL & ROONEY PC	55291	GALEPHAR PHARMACEUTICAL RESEARCH INC.	2021	second_quarter	PHA	Strategy development and implementation of federal government relations initiatives relating to the Food and Drug Administrations Pre-Approval of Supplemental through New Drug Application (NDA).	HOUSE OF REPRESENTATIVES,SENATE	20000		0	0	2021-07-10T07:10:54.357000-04:00